Charles Explorer logo
🇨🇿

Perioperative anticoagulation management during thoracoscopic ablation

Publikace na 3. lékařská fakulta |
2017

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

With interest we read the article by Romanov et al in the September issue of HeartRhythm.1 They reported that 6 strokes/ transient ischemic attacks (TIAs) occurred perioperatively: 4 (4.5%) in patients undergoing thoracoscopic pulmonary vein isolation þ box lesion only and 2 (2.2%) in patients who underwent an additional occlusion of the left atrial appendage (LAA).1 The exact peri- and postoperative anticoagulation protocol was not reported. Compared with other articles on thoracoscopic ablation (TA) or hybrid ablation, the absence of a description of the peri- and postoperative anticoagulation stands out in this article.

In our recent report, 1 stroke and 5 asymptomatic thrombi occurred in 17 patients who underwent TA without heparin and without LAA occlusion, but no strokes or asymptomatic thrombi occurred while on heparin and if the LAA was occluded.2 Compared with endocardial catheter ablation, the risk of stroke/TIA seems to be higher during TA; for example, Probst et al 3 reported 5.1%strokes/TIAs. Therefore, one would expect precise reporting of anticoagulation used perioperatively to address this issue.

Unfortunately, the opposite seems to be true; clear description of peri- and postoperative anticoagulation management is obviously lacking.1,3 This is in stark contrast to articles on catheter ablation, in which the anticoagulation protocol is described in detail. In articles on TA, typically the only anticoagulation information given is with regard to withdrawal of warfarin or novel oral anticoagulants before ablation